Saturday 04 May 2024
By
main news image

KUALA LUMPUR (March 18): Hong Leong Investment Bank (HLIB) maintained its 'buy' rating for Sunway Bhd at RM3.02, with a higher target price (TP) of RM3.76 (from RM3.10), and said Sunway’s healthcare segment achieved an impressive four-year compound annual growth rate of 34.9% in earnings before interest, taxes, amortisation and depreciation (Ebitda) from the financial year ended Dec 31, 2019 (FY2019) fo FY2023, while its Ebitda margin of 26% sat at the upper end of the industry's average range.

In a note on Monday, the research house said that based on its sensitivity analysis, valuation of Sunway Healthcare Group, anticipated to be listed by end-FY2027, could potentially range from RM22.4 billion to RM28.9 billion, reflecting its superior Ebitda margin and other competitive advantages.

“Sunway's diversified business portfolio, deeply entrenched in Malaysia's economic progress, presents an opportunity for investors to own a piece of the nation's robust growth trajectory.

“We maintain 'buy', with a higher TP of RM3.76 (from RM3.10), based on sum-of-parts-derived valuation,” HLIB said.

      Print
      Text Size
      Share